Have you ever wondered about the true impact of Artificial Intelligence (AI) in the BioHealth industry? In this episode of BioTalk with Rich Bendis, we have the privilege of hosting Dr. Juergen Klenk, a Principal at Deloitte and a Board Member at BioHealth Innovation. Dr. Klenk brings a wealth of expertise and experience with a unique background combining formal scientific training and entrepreneurial ventures.
Join us as we embark on an insightful discussion about the current state of AI in the BioHealth industry, diving deep into the realities and challenges of this cutting-edge technology. Dr. Klenk shares his interest in AI and the reasons behind its increasing prominence in the field. We explore the historical origins of the AI hype cycle and how we've reached the stage we're in today.
Listen now via your favorite podcast platform:
- Apple Podcasts: 🍎🎙️ - https://apple.co/41u5PtL
- Google Podcasts: 🔍🎧 - https://bit.ly/41z2f1O
- Spotify: 💚🎶 - https://spoti.fi/470FMeZ
- Amazon Music: 📦🎵 - https://amzn.to/3tpILzZ
- TuneIn: 📻🔊 - https://bit.ly/3RvUF3l
Discover tangible examples that illustrate AI's true value, benefits, and impact in BioHealth. Dr. Klenk sheds light on the underlying key technologies that power AI and the associated challenges and risks.
Looking to the future, we examine the outlook for AI in the coming months, years, and even this decade. Will the AI hype continue, or will we witness substantial breakthroughs and transformations? Dr. Klenk offers valuable insights into what organizations can and should do to ride the AI wave effectively.
Don't miss this engaging conversation with Dr. Juergen Klenk as we navigate the exciting world of AI in the BioHealth industry. Tune in now to gain a deeper understanding of AI's reality and its potential to shape the future of healthcare and research.
Dr. Juergen Klenk is a Principal with Deloitte’s Strategy & Analytics practice and serves as the Federal Health sector’s Data & AI lead. Trained as a mathematician, his work focuses on the responsible and equitable application of data science and technology to biomedical and clinical research. Dr. Klenk has supported the NIH, FDA, CDC, CMS and other HHS operating divisions for the past 17 years. In recent years, his work has focused advancing the principles of open science, open data, and open platforms for research. Dr. Klenk earned a PhD in Mathematics and MS in Physics and Mathematics from Eberhard-Karls-Universität Tübingen (Germany) and conducted research at the Australian National University in Canberra (Australia) and at Yale University.